title: Reply to "What types of Candida infections should be included when evaluating breakthrough infections during posaconazole prophylaxis?".
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Dolton
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: McLachlan
mesh_terms: D000935:Antifungal Agents / Q000493:pharmacokinetics*; D016903:Drug Monitoring; D005260:Female; D005658:Fungi / Q000187:drug effects*; D006801:Humans; D008297:Male; D009181:Mycoses / Q000097:blood* / Q000517:prevention & control*; D014230:Triazoles / Q000493:pharmacokinetics*
chemical_list: D000935:Antifungal Agents; D014230:Triazoles